Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike protein receptor binding domain displayed on a two-component protein nanoparticle (RBD-NP), to stimulate robust and durable neutralizing antibody (nAb) responses and protection against SARS-CoV-2 in non-human primates. We evaluated five different adjuvants combined with RBD-NP including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an alpha-tocopherol-containing squalene-based oil-in-water emulsion used in pandemic influenza vaccines; AS37, a TLR-7 agonist adsorbed to Alum; CpG 1018-Alum (CpG-Alum), a TLR-9 agonist formulated in Alum; or Alum, the most widely used adjuvant. All five adjuvants induced substantial nAb and CD4 T cell responses after two consecutive immunizations. Durable nAb responses were evaluated for RBD-NP/AS03 immunization and the live-virus nAb response was durably maintained up to 154 days post-vaccination. AS03, CpG-Alum, AS37 and Alum groups conferred significant protection against SARS-CoV-2 infection in the pharynges, nares and in the bronchoalveolar lavage. The nAb titers were highly correlated with protection against infection. Furthermore, RBD-NP when used in conjunction with AS03 was as potent as the prefusion stabilized Spike immunogen, HexaPro. Taken together, these data highlight the efficacy of the RBD-NP formulated with clinically relevant adjuvants in promoting robust immunity against SARS-CoV-2 in non-human primates.

Article activity feed

  1. SciScore for 10.1101/2021.02.10.430696: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIACUC: Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variableAnimal subjects and experimentation: Thirty-three male rhesus macaques (Macaca mulatta) of Indian origin, aged 3 - 9 years were assigned to the study (Supplementary Table 1).
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    In wells with anti-human IgG capture antibody, human IgG control (SinoBiological, #HG1K) was serially diluted from 0.5-500 ng/mL in TBST in triplicate and 50 μL of each dilution incubated for 1 h.
    anti-human IgG
    suggested: None
    The antibody-virus mixture was added to VeroE6 cell (C1008, ATCC, #CRL-1586
    C1008
    suggested: None
    assay: Antibodies blocking the binding of SARS-CoV-2 Spike RBD to the angiotensin-converting enzyme 2 (ACE2) were detected with a V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit (Meso Scale Diagnostics) according to the manufacturer’s instructions.
    ACE2
    suggested: None
    Luminex Isotype and FcR Binding Assay: To determine relative concentrations of antigen-specific antibody isotypes and Fc receptor binding activity, a Luminex isotype assay was performed as previously described39.
    antigen-specific
    suggested: None
    Mouse-anti-rhesus antibody detectors were then added for each antibody isotype (IgG1, IgG2, IgG3, IgG4, IgA, NIH Nonhuman Primate Reagent Resource supported by AI126683 and OD010976).
    IgG1 , IgG2
    suggested: None
    IgG3 , IgG4
    suggested: None
    Tertiary anti-mouse-IgG detector antibodies conjugated to PE were then added.
    anti-mouse-IgG detector
    suggested: None
    Systems serology: To quantify antibody functionality of plasma samples, bead-based assays were used to measure antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP) and antibody-dependent complement deposition (ADCD), as previously described40-43.
    antibody-dependent neutrophil phagocytosis ( ADNP
    suggested: None
    antibody-dependent complement deposition ( ADCD)
    suggested: None
    SARS-CoV-2 spike protein (Hexapro antigen from Erica Ollmann Saphire, La Jallo for Immunology) was coupled to fluorescent streptavidin beads (Thermo Fisher) and incubated with sera samples to allow antibody binding to occur.
    SARS-CoV-2 spike protein ( Hexapro antigen from Erica Ollmann Saphire , La Jallo for Immunology )
    suggested: None
    SARS-CoV-2 spike protein ( Hexapro antigen from Erica Ollmann Saphire ,
    suggested: None
    After phagocytosis of immune complexes, neutrophils were stained with an anti-CD66b Pacific Blue detection antibody (Biolegend) prior to flow cytometry.
    anti-CD66b
    suggested: None
    For quantification of antibody-dependent NK cell activation, diluted plasma samples were incubated in Nunc MaxiSorp plates (Thermo Fisher Scientific) coated with antigen.
    antigen .
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Anti-S binding ELISA: SARS-CoV-2 Spike protein was produced in HEK293T cells (Atum, Newark, CA)
    HEK293T
    suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)
    For neutralization assays, HEK-hACE2 cells were cultured in DMEM with 10% FBS (Hyclone) and 1% PenStrep with 8% CO2 in a 37°C incubator on poly-lysine (sigma) 96 well plates.
    HEK-hACE2
    suggested: None
    Pseudovirions were produced in HEK293T/17 cells by co-transfection of a lentivirus backbone plasmid, a Spike-expressing plasmid, and a firefly Luc reporter gene plasmid.
    HEK293T/17
    suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)
    The furin cleavage site, a site with frequent culture adaptation in Vero E6 cells, harbored no polymorphisms at greater than 1% of sequence reads in this stock.
    Vero E6
    suggested: RRID:CVCL_XD71)
    For ADCP, cultured human monocytes (THP-1 cell line) were incubated with immune complexes, during which phagocytosis occurred.
    THP-1
    suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)
    Software and Algorithms
    SentencesResources
    Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources.
    NIRC
    suggested: None
    Alum (Alhydrogel 2%) was purchased from Croda Healthcare (Batch #0001610348).
    Croda Healthcare
    suggested: None
    Plates were immediately read at 450 nm on a SpectraMax M5 plate reader (Molecular Devices) and data plotted and fit in Prism (GraphPad) using nonlinear regression sigmoidal, 4PL, X is log(concentration) to determine EC50 values from curve fits.
    Prism
    suggested: (PRISM, RRID:SCR_005375)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)
    All flow cytometry data were analyzed using Flowjo software v10 (TreeStar Inc.)
    Flowjo
    suggested: (FlowJo, RRID:SCR_008520)
    Before analysis, the PET images were Gaussian smoothed in OsiriX and smoothing was applied to raw data with a 3 x 3 matrix size and a matrix normalization value of 24.
    OsiriX
    suggested: None
    PET quantification values were organized in Microsoft Excel.
    Microsoft Excel
    suggested: (Microsoft Excel, RRID:SCR_016137)
    All the statistical analyses were performed using GraphPad Prism v.9.0.0 or R version 3.6.1.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.